Evidence map›Paper›PMID 35032865›Full record

ArticleVirology2022

Rift Valley fever virus Gn V5-epitope tagged virus enables identification of UBR4 as a Gn interacting protein that facilitates Rift Valley fever virus production.

Nicole Bracci, Cynthia de la Fuente, Sahar Saleem, Chelsea Pinkham, Aarthi Narayanan, Adolfo García-Sastre, Velmurugan Balaraman, Juergen A Richt, William Wilson, Kylene Kehn-Hall

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Pseudotyped Viruses for Phlebovirus.Advances in experimental medicine and biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Nicole BracciDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, USA; National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA.
Cynthia de la FuenteThe National Institutes of Health, National Institute of Allergy and Infectious Diseases, DEA, USA; National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA.
Sahar SaleemNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA.
Chelsea PinkhamNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA.
Aarthi NarayananNational Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, USA.
Velmurugan BalaramanDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, USA.
Juergen A RichtDepartment of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, USA.
William WilsonNational Bio and Agro-Defense Facility, Agricultural Research Service, USDA, USA.
Kylene Kehn-HallDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, USA; National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, USA; Center for Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State University, USA. Electronic address: kkehnhall@vt.edu.
George Mason University · USKansas State University · USAgricultural Research Service · USIcahn School of Medicine at Mount Sinai · USNational Institutes of Health · US

Funding

Sex-specific effects of obestity on Influenza A virus infection and immunityP20GM130448 · NIGMS · KANSAS STATE UNIVERSITY · PI WAITHAKA MWANGI · 2020 to 2026
$15.8M
NIGMS NIH HHS P20 GM130448
6 · The paper itself

Abstract

Rift Valley fever virus (RVFV) is an arbovirus that was first reported in the Rift Valley of Kenya which causes significant disease in humans and livestock. RVFV is a tri-segmented, negative-sense RNA virus consisting of a L, M, and S segments with the M segment encoding the glycoproteins Gn and Gc. Host factors that interact with Gn are largely unknown. To this end, two viruses containing an epitope tag (V5) on the Gn protein in position 105 or 229 (V5Gn105 and V5Gn229) were generated using the RVFV MP-12 vaccine strain as a backbone. The V5-tag insertion minimally impacted Gn functionality as measured by replication kinetics, Gn localization, and antibody neutralization assays. A proteomics-based approach was used to identify novel Gn-binding host proteins, including the E3 ubiquitin-protein ligase, UBR4. Depletion of UBR4 resulted in a significant decrease in RVFV titers and a reduction in viral RNA production.

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralCalmodulin-Binding ProteinsCell LineCell Line, TumorCulexEpitopesGene Expression ProfilingGene Expression RegulationHEK293 CellsHepatocytesHost-Pathogen InteractionsHumansProtein BindingRift Valley fever virusAntibodies, NeutralizingAntibodies, ViralCalmodulin-Binding ProteinsEpitopesUbiquitin-Protein LigasesUBR4 protein, humanViral Envelope ProteinsGlycoproteinsGnRift valley fever virusUBR4

Identifiers

PMID35032865
PMCPMC8877469
OpenAlexW4206004836

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.